Tasisulam

Confirm delete?

Tasisulam

Zoom

Cat No: 21556

Biochemicals - More Biochemicals

Tasisulam is an anticancer agent that inhibits the growth of Calu-6 non-small cell lung carcinoma (NSCLC) and A-375 melanoma cell lines (EC50s = 10 and 25 μM, respectively).{39589} It arrests the cell cycle at the G2/M phase and induces apoptosis of C...

This product can only be bought through Cayman Chemical. Please contact us.

Product Overview
Data
Downloads
About Cayman

Territorial Availability: Available through Bertin Technologies only in France

Synonyms:

N-[(5-bromo-2-thienyl)sulfonyl]-2,4-dichloro-benzamide

Correlated keywords:

LY-573636 anti-tumor cancer Calu6 nonsmall A375 G2M nonapoptotic neo-angiogenesis

Product Overview:
Tasisulam is an anticancer agent that inhibits the growth of Calu-6 non-small cell lung carcinoma (NSCLC) and A-375 melanoma cell lines (EC50s = 10 and 25 μM, respectively).{39589} It arrests the cell cycle at the G2/M phase and induces apoptosis of Calu-6 cells in a concentration-dependent manner. Tasisulam induces non-apoptotic growth arrest in human vascular endothelial cells (HUVECs) and inhibits VEGF-, FGF-, and EGF-induced endothelial cord formation in vitro (EC50s = 47, 103, and 34 nM, respectively). In vivo, tasisulam (25 and 50 mg/kg) reduces hemoglobin content and blood vessel density in a Matrigel™ plug model of neoangiogenesis. It also reduces tumor growth in a dose-dependent manner in a Calu-6 mouse xenograft model via arrest of the cell cycle at the G2/M phase, induction of apoptosis, and reduction of tumor blood vessel density. Formulations containing tasisulam are under clinical investigation for the treatment of advanced solid tumors.

Size	5 mg
Shipping	dry ice
CAS Number	519055-62-0
Molecular Formula	C₁₁H₆BrCl₂NO₃S₂
SMILES	ClC1=CC=C(C(NS(=O)(C2=CC=C(Br)S2)=O)=O)C(Cl)=C1
Molecular Weight	415,1
Formulation	A crystalline solid
Purity	≥98%
Custom Code	2903.99
UNSPSC code	12352100

Technical File

MSDS

Click here to ask for your quote and get 15% off Cayman's products.

Cayman Chemical's mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.

Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.

Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.

Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.

Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009

Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.